Substance
ID:67
Names and Identifiers
Synonyms
1-Methyl-2-phenylethylamine3-Methoxyamphetamine3-Methoxyphenylisopropylaminebeta-AminopropylbenzeneFenylo-izopropylaminylPhenylisopropylamine(+/-)-beta-Phenylisopropylaminem-MethoxyamphetamineMethamphetamine HCL[1-(3-Methoxyphenyl)-2-propyl]amineAmfetamine(+/-)-Benzedrinedl-1-Phenyl-2-aminopropanedl-Amphetaminedl-Benzedrinem-Methoxy-a-methylphenethylaminealpha-MethylbenzeneethaneamineAmphetamine SulfateDL-alpha-Methylphenethylaminebeta-phenyl-isopropylamineAmphetamine(+/-)-Desoxynorephedrine1-Phenyl-2-aminopropane3-Methoxy-a-methylbenzeneethanamine
Brand Name
SympaminDextrostatDesoxynDexedrineAnorexideElastononIsoamycinIsoamyneIsomynPhenamineFerndexFinamNorephedraneOrtedrineBenzedrineWeckamineNovydrineParedrineRhinalatorSympamineBenzoloneDexampexFenaminMethampexAdipanAnorexineSimpatinaSympatedrineOktedrinPercomonPhenedrineProfaminaPropisamineSimpatedrinPsychedrineRaphetamineActedronAllodeneBenzebarMecodrin
IUPAC Traditional name
dextroamphetamine
IUPAC name
(2S)-1-phenylpropan-2-amine
Registration numbers
CAS Number
Properties
Physical Property
Solubility
Slightly
Hydrophobicity(logP)
1.8
Molecule Details
Drug Groups
illicit; approved
Description
Amphetamine is a chiral compound. The racemic mixture can be divided into its optical antipodes: levo- and dextro-amphetamine. Amphetamine is the parent compound of its own structural class, comprising a broad range of psychoactive derivatives, e.g., MDMA (Ecstasy) and the N-methylated form, methamphetamine. Amphetamine is a homologue of phenethylamine.
Indication
For treatment of Attention Deficit Disorder with Hyperactivity (ADDH) and narcolepsy in children.
Pharmacology
Amphetamine and dextroamphetamine, non-catechloamine sypathomimetic agents, are used in combination to treat attention-deficit hyperactivity disorder (ADHD) or narcolepsy. Adderall consists of equivalent amounts of amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate.
Toxicity
LD50=180 mg/kg(subcutaneous injection in rat). The most common presenting symptoms seen are agitation, hallucinations, suicidal behaviour, and chest pain.
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic
Absorption
Amphetamine forms easily absorbed molecules that are highly lipid soluble
Half Life
10 hours
Protein Binding
15-40%
References
•
Leith NJ, Kuczenski R: Chronic amphetamine: tolerance and reverse tolerance reflect different behavioral actions of the drug. Pharmacol Biochem Behav. 1981 Sep;15(3):399-404.
[Pubmed]
•
Chaudhry IA, Turkanis SA, Karler R: Characteristics of "reverse tolerance" to amphetamine-induced locomotor stimulation in mice. Neuropharmacology. 1988 Aug;27(8):777-81.
[Pubmed]
•
Sax KW, Strakowski SM: Behavioral sensitization in humans. J Addict Dis. 2001;20(3):55-65.
[Pubmed]
•
Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33.
[Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005 Apr;75(6):406-33. Pubmed
• Chaudhry IA, Turkanis SA, Karler R: Characteristics of "reverse tolerance" to amphetamine-induced locomotor stimulation in mice. Neuropharmacology. 1988 Aug;27(8):777-81. Pubmed
• Sax KW, Strakowski SM: Behavioral sensitization in humans. J Addict Dis. 2001;20(3):55-65. Pubmed
• Leith NJ, Kuczenski R: Chronic amphetamine: tolerance and reverse tolerance reflect different behavioral actions of the drug. Pharmacol Biochem Behav. 1981 Sep;15(3):399-404. Pubmed